{
    "title": "103_hr1926",
    "content": "The \"National Narcotics Leadership Act Amendments of 1993\" allows the Director to request funding for specific initiatives in line with the President's priorities for the National Drug Control Strategy. Additionally, there are amendments regarding the implementation of the National Drug Control Strategy. The National Narcotics Leadership Act of 1988 is amended to require the Director to report quarterly to Congress on the need for reprogramming funds over $5,000,000. Additionally, a new restriction prohibits federal officers in the Office of National Drug Control Policy from participating in federal election campaign activities. The National Narcotics Leadership Act of 1988 is amended to require the Director to report quarterly to Congress on the need for reprogramming funds over $5,000,000. Additionally, federal officers in the Office of National Drug Control Policy are prohibited from participating in federal election campaign activities. National Drug Control Strategy Outcome Measures are established. Section 1005(a) of the National Narcotics Leadership Act of 1988 is amended to include an evaluation of Federal drug control effectiveness in the National Drug Control Strategy. This evaluation assesses the reduction of drug use through various surveys and studies, including high-risk populations. The evaluation of Federal drug control effectiveness in the National Drug Control Strategy includes estimates of drug prevalence and frequency of use among high-risk populations and in the workplace, as well as assessment of the reduction of drug availability in the United States. The evaluation of drug availability in the United States includes measuring the quantities of cocaine, heroin, and marijuana available, amount of drugs entering the country, hectares of poppy and coca cultivated, drugs seized, processing labs destroyed, changes in price and purity, and controlled substances diverted from legitimate retail. The assessment includes measuring drug availability by evaluating quantities of cocaine, heroin, and marijuana, drug entry into the country, cultivation of poppy and coca, seized drugs, destroyed processing labs, changes in price and purity, controlled substances diversion, and effectiveness of technology programs at US ports of entry. It also involves estimating the impact of drug use on hospital emergency rooms in the US. The assessment involves estimating the burdens drug users place on hospital emergency rooms in the United States, including drug-related services provided, national healthcare costs of drug use, drug-related crime, contribution of drugs to the underground economy, and the status of drug treatment. The assessment includes estimating the impact of drug users on hospital emergency rooms, national healthcare costs, drug-related crime, and the contribution of drugs to the underground economy. It also evaluates the status of drug treatment in the United States, including treatment capacity, availability for intravenous drug users and pregnant women, and the number of drug users. The assessment evaluates the availability of treatment for intravenous drug users and pregnant women within each State, estimates the number of drug users who could benefit from treatment, and assesses the success of drug treatment programs at federal and state levels. It also examines the quality of substance abuse treatment programs, qualifications of treatment personnel, and the admission process for patients. The Director shall assess drug use measurement instruments and techniques, coverage of national drug use measurement tools, and the population at risk for drug use in the National Drug Control Strategy. The Director will assess existing national drug use measurement instruments and techniques, identify deficiencies, and propose remedies to improve treatment availability. Federal agencies collecting drug-related information must cooperate with the Director. The Director will assess drug use and availability in the US and report to the President and Congress. Federal agencies must cooperate with the Director for data collection. The Director of the Office of National Drug Control Policy is added as a member of the National Security Council. Additionally, a Counter-Drug Technology Assessment Center is established. The National Narcotics Leadership Act of 1988 is amended to support the application of technology in drug treatment through interagency agreements or grants subjected to peer review. Additionally, the Advanced Research Project Agency provides assistance and support to the Office of National Drug Control. The National Narcotics Leadership Act of 1988 is amended to provide assistance and support from the Advanced Research Project Agency to the Office of National Drug Control Policy. Section 1008 is repealed and redesignated to follow section 1007. SEC. 7. The Director may pay for necessary expenses for consultation on the National Drug Control Strategy. SEC. 8. Authorization of appropriations for fiscal year 1994. SEC. 9. The Office of National Drug Control Policy terminates on September 30, 1994. Section 1009 of the National Narcotics Leadership Act of 1988 is amended to terminate the Office of National Drug Control Policy on September 30, 1994."
}